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Abstract
AIM: To assess the acceptance, safety and efficacy 
of care and treatment for chronic hepatitis C (CHC) in 
drug addicts. 
METHODS: We designed a multidisciplinary, phase IV 
prospective cohort study. All illicit drug users (IDUs) 
visited a Territorial Addiction Service (SerT) in the 
District of Brescia, and hepatitis C antibody (HCVAb) 
testing positive were offered as part of a standardised 
hepatologic visit in our Gastroenterology Unit. Patients 
with confirmed CHC and without medical contraindica-
tions were administered peginterferon alfa-2b 1.5 µg/
kg per week plus ribavirin (800-1400 mg/d) for 16-48 
wk. All IDUs were unselected because of ongoing ad-
diction and read and signed an informed consent form. 
Virologic responses at weeks 4 and 12 of therapy, at 
the end of treatment and 24 wk after the end of treat-
ment were the main measures of efficacy. Adherence 
was estimated according to the 80/80/80 criteria. 
RESULTS: From November 2007 to December 2009, 
162 HCVAb+ IDUs were identified. Sixty-seven patients 
(41% of the initial cohort) completed the diagnostic 
procedure, and CHC was diagnosed in 54 (33% of the 
total). Forty-nine patients were offered therapy, and 39 
agreed (80% of acceptance rate). The prevalent HCV 
genotype was type 1, and the HCV RNA baseline level 
was over 5.6 log/mL in 61% of cases. Five patients 
dropped out, two because of severe adverse events 
(SAEs) and three without medical need. Twenty-three 
and 14 patients achieved end of treatment responses 
(ETRs; 59%) and sustained virologic responses (SVRs; 
36%), respectively. Thirty-one patients were fully com-
pliant with the study protocol (80% adherence). The 
prevalence of host and viral characteristics negatively 
affecting the treatment response was high: age over 
40 years (54%), male gender (85%), overweight body 
type (36%), previous unsuccessful antiviral therapy 
(21%), HCV genotype and viral load (60% and 62%, 
respectively), earlier contact with HBV (40%) and st-
eatosis and fibrosis (44% and 17%, respectively). In a 
univariate analysis, alcohol intake was associated with 
a non-response (P  = 0.0018, 95%CI: 0.0058-0.4565). 
CONCLUSION: Drug addicts with CHC can be success-
fully treated in a multidisciplinary setting using standard 
antiviral combination therapy, despite several “difficult 
to reach, manage and treat” characteristics.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The paper reports results from a clinical trial 
on the management of chronic hepatitis C (CHC) in il-
licit drug users (IDUs). Two key elements characterise 
the trial: (1) the study was performed by a multidis-
ciplinary team; and (2) the patients were unselected 
because of ongoing addiction. We assessed the ac-
ceptance of care and treatment for CHC among IDUs, 
who are classically considered to be a “difficult to reach 
and manage” group. For the IDUs accepting antiviral 
treatment, we analysed results on safety, efficacy and 
adherence and on the prevalence of negative prognos-
tic factors affecting the virologic response to address 
whether IDUs are also “difficult to treat” patients.
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INTRODUCTION
Hepatitis C virus (HCV) is estimated to chronically infect 
more than 180 million people worldwide, with approxi-
mately 4 million carriers in Europe alone[1]. The progno-
sis of  chronic hepatitis C (CHC) is related to fibrosis pro-
gression, and the development of  cirrhosis varies from 
5%-25% over an average period of  30 years[2]. According 
to a recently validated mathematical model, morbidity 
and mortality from HCV are expected to rise in 2010 and 
to peak between 2030 and 2035[3]. The main reasons for 
this negative forecast are the low rates of  screening for 
HCV and of  treatment for CHC. The World Health Or-
ganization has defined chronic infection with HCV as a 
public health problem of  primary importance, and during 
a consensus meeting in May 2010, all health authorities 
were invited to strive to prevent, identify and rapidly treat 
the infection[1].
In developed countries, HCV is mainly transmitted 
by needles during drug injections, and illicit drug users 
(IDUs) are considered to be the largest group affected 
by HCV, accounting for 20%-50% of  cases of  chronic 
infection[4]. A recent paper estimating viral transmission 
showed, for the first time, that HCV “super-spreading” 
is led by IDUs. According to this estimation model, each 
infected IDU is likely to infect approximately 20 other 
people, half  of  whom will be infected within 2 years of  
the initial infection[5].
International authorities on liver diseases (i.e., the Na-
tional Institutes of  Health since 2002, the American Gas-
troenterological Association since 2006 and the American 
Association for the Study of  the Liver since 2009) rec-
ommend the treatment of  CHC in IDUs and encourage 
clinical studies in chronically infected IDUs “to evaluate 
the safest and most effective treatment, factors favouring 
compliance, risk of  relapse, side-effect profile and the 
impact of  methadone maintenance treatment”[6-8]. 
Despite international recommendations, several bar-
riers to treating IDUs persist not only among physicians 
but also among IDUs[9,10]. Physicians’ concerns mainly in-
clude IDUs’ chaotic lifestyle; IDUs’ possibly poor adher-
ence to treatment; difficulties in the management of  the 
psychiatric side effects of  treatment, which are believed 
to be more frequent among IDUs; and the risk of  re-in-
fection after HCV eradication[10]. The risk of  relapse into 
addiction due to interferon (IFN)-driven mood changes 
and the use of  needles in CHC therapy, is also described 
as a relative contraindication to IFN treatment in IDUs, 
although the data from prospective trials on this risk are 
scarce[11,12]. Concerns about antiviral therapy for CHC 
are also present among IDUs: their conception of  illness 
and death is often different, for cultural reasons, from 
the beliefs of  the general population, and information 
on the natural history and treatment challenges of  HCV 
is inexact or incomplete[10]. Moreover, factors including 
precarious working conditions, a lack of  fixed adobe, un-
documented migrant status and social isolation can affect 
access to care and treatment for liver diseases, and special 
efforts may be necessary to reach IDUs in their social 
environment[13]. In our recent review on the subject[14], 
we report that due to the barriers to treatment, most 
published prospective trials on the treatment of  CHC in 
IDUs involve limited numbers of  patients, ranging from 
11-71, have no standardised intervention protocol and 
are mainly restricted to abstinent patients.
As an overview, IDUs are perceived as patients who 
are difficult to reach for social reasons and difficult to 
manage because of  lifestyle. Moreover, no previous study 
has assessed whether IDUs are also difficult to treat 
because of  the presence of  negative prognostic factors, 
either viral or host-related, affecting the rate of  success 
of  antiviral therapy. For these difficulties to be addressed, 
and to successfully be able to contact, manage and treat 
these patients, a multidisciplinary approach is manda-
tory. This approach should involve health professionals 
engaged in the management of  addiction and dedicated 
hepatologists with a highly personalised approach to pa-
tient care. 
We performed a prospective clinical study designed to 
maximise IDUs’ access to treatment for HCV infection 
by involving both the physicians directly engaged in the 
management of  addiction and the specialised hepatolo-
gist in our unit and by avoiding “a priori” exclusion crite-
ria for antiviral therapy of  active IDUs. The main objec-
tives of  the study were to specifically evaluate the rate of  
access to clinical care; the acceptance, safety and efficacy 
of  antiviral treatment for CHC; and the prognostic fac-
tors for responses to standard antiviral therapy in a large 
cohort of  IDUs, who were unselected because of  ongo-
ing addiction.
MATERIALS AND METHODS
Study design
We designed a multidisciplinary, phase IV prospective 
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cohort study. The multidisciplinary approach was ensured 
by close collaboration between six Territorial Addiction 
Services (SerT) of  the Local Health Authority of  the 
District of  Brescia (ASL) and our Gastroenterology Unit 
(GU, Spedali Civili and University of  Brescia). The physi-
cians of  the SerT were responsible for the identification 
of  patients with hepatitis C antibody (HCVAb) positivity 
among those individuals visiting the SerT clinic. Based on 
the protocol definition, patients with “ongoing addiction 
problems”, actively using illicit drugs and/or alcohol or 
in a supportive/substitution treatment program, were all 
considered to be subjects. The SerT physicians were also 
responsible for collecting all demographic, social, psycho-
logical and addiction data in a standardised case report 
form. The patients selected by the SerT physicians were 
instructed to call a dedicated telephone number to make 
an appointment for an initial standard hepatologic evalu-
ation in the GU, including a medical visit, laboratory tests 
and ultrasound evaluation. The aims of  the hepatologic 
evaluation were to confirm HCV-related chronic hepati-
tis, to assess the severity of  liver disease and to evaluate 
eligibility for antiviral treatment. A liver biopsy was not 
routinely performed. The patients with confirmed CHC 
and meeting standard criteria for HCV therapy[8] were 
offered antiviral treatment with pegylated interferon and 
ribavirin, according to the study protocol for treatment, 
and were asked to sign an informed consent form. To 
improve adherence, a mobile telephone number was acti-
vated for all patients on antiviral treatment, with a physi-
cian on call every day from 8 a.m. to 1 p.m.
Selection criteria
The inclusion criteria were as follows: over 18 years of  
age, HCV RNA detected with a sensitive polymerase 
chain reaction (PCR) (cut-off  of  determination 50 IU/
mL; COBAS Amplicor HCV test, Roche Diagnostics, 
Branchberg, NJ, United States) and confirmed on at 
least two occasions over a period of  6 mo, compensated 
liver disease (Child-Pugh score ≤ 5), absence of  major 
medical contraindications to antiviral therapy (including 
malignancies, severe cardiac illness and uncontrolled psy-
chiatric condition), willingness to avoid pregnancy during 
the entire treatment period and during the 6 mo after the 
last ribavirin dose intake, ability to read and sign a written 
informed consent form and willingness to adhere to the 
study protocol for treatment. Patients with suspected or 
confirmed idiosyncratic reactions to interferon or ribavi-
rin were excluded.
Treatment protocol
The study protocol for treatment consisted of  peginter-
feron alfa-2b (12 kDa) 1.5 µg/kg per week plus ribavirin 
800-1400 mg according to body weight (800 mg for < 65 
kg, 1000 mg for 65-80 kg, 1200 mg for 81-105 and 1400 
mg for > 105 kg) divided into two daily administrations.
The duration of  the treatment was 24 wk for HCV 
genotypes 2/3 and 48 wk for HCV genotypes 1/4. The 
achievement of  a rapid virologic response (RVR; HCV 
RNA < 50 IU/mL at week 4 of  therapy) was regarded as 
an indication for short-term therapy in all naïve patients 
fulfilling the criteria of  no dose reduction during the first 
4 wk of  therapy, low baseline viral load (HCV RNA < 
600000 IU/mL) and the absence of  cirrhosis. The short-
term scheme consisted of  16 wk for HCV genotypes 2/3 
and 24 wk for HCV genotypes 1/4. Treatment was dis-
continued prematurely, according to international rules[8] 
(at week 12 if  the HCV RNA level drops by < 2 Log 
and at week 24 if  the HCV RNA level is > 50 IU/mL); 
in the case of  virologic breakthrough; in the presence of  
severe adverse events (SAEs); or upon patients’ request, 
with no need for explanation. In the case of  a virologic 
breakthrough, HCV genotyping [line probe assay (LIPA), 
Bayer HealthCare, Tarrytown, NY, United States] was 
performed to exclude mixed/new HCV infections.
Adverse reactions to interferon and/or ribavirin were 
managed according to international guidelines[8], and the 
use of  erythropoietin and leucocyte growth factors was 
allowed, according to the current Italian Drug Agency 
(AIFA) recommendations.
The timetable of  the study was as follows: a medical 
visit including a general physical examination, an assess-
ment of  body mass index, the administration of  AU-
DIT-C for screening for at-risk alcohol-related behaviour 
and a Hamilton Test for scoring anxiety and depression. 
The measurement of  the complete blood count and the 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST) and γ-glutamyl transferase (GGT) levels was 
requested every 4 wk during treatment and 24 wk after 
the end of  therapy. Blood tests, including for thyroid 
function (FT4 and TSH), autoimmunity (ANA, AMA, 
LKM and ASMA) and liver function (albumin, PT and 
bilirubin), were mandatory at the beginning and every 12 
wk of  treatment. Quantitative and qualitative assays for 
HCV RNA were requested at week 0-4-12 and at week 
4-12-24 of  treatment, at the end of  therapy and 24 wk 
after the end of  therapy, respectively.
Outcome measures
Access to liver care was calculated as the proportion of  
IDUs attending the first hepatologic visit and complet-
ing the diagnostic procedure among all HCVAb+ IDUs 
screened by the SerT and showing interest in this oppor-
tunity. Access to therapy was evaluated as the proportion 
of  patients starting antiviral therapy among the eligible 
patients. The main measure of  safety was the rate of  
withdrawal for SAEs, according to the Common Ter-
minology Criteria for Adverse Events v3.0[15]. The main 
outcome measure of  efficacy was the sustained virologic 
response (SVR; HCV RNA persistently < 50 IU/mL 24 
wk after treatment discontinuation) among the treated 
patients. Secondary efficacy measures were the achieve-
ment of  an RVR, an early virologic response (EVR; HCV 
RNA < 50 IU/mL at week 12 of  therapy) and an end of  
treatment response (ETR; HCV RNA < 50 IU/mL at 
the end of  therapy). Adherence was estimated according 
to the 80/80/80 criteria (80% of  pegylated interferon, 
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Table 2  Type of addiction and opiate substitution treatment 
among the hepatitis C antibody+ illicit drug users selected 
by the Territorial Addiction Service and comparison with 
hepatitis C antibody+ illicit drug users accepting antiviral 
therapy  n  (%)
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had comorbidities (Table 1). The prevalent type of  ad-
diction was intravenous injection of  heroin, with a mean 
duration of  13 years. Most patients were on opiate sub-
stitution treatment, with 66% on methadone and 12% on 
buprenorphine. All patients in methadone maintenance 
therapy received a dose lower than 100 mg/d (Table 2). 
Most IDUs who received information about HCV infec-
tion from health operators, the press or television were 
not confident about their knowledge and had moderate 
worries about the side effects of  HCV therapy (Table 3).
Access to care and treatment
Patient disposition, according to the study protocol, is re-
ported in Figure 1. Access to the first hepatologic work-
up was observed in 106 patients, which was 65% of  the 
initial cohort. Although 56 IDUs expressed interest in 
the opportunity for a dedicated medical examination to 
a SerT doctor, these individuals never called our clinic 
for an appointment. Sixty-seven patients completed the 
diagnostic procedure, or 41% of  the initial cohort, cor-
responding to 63% of  patients visiting our clinic for 
an initial evaluation. Patients who did not adhere to the 
diagnostic protocol (39 IDUs) were all contacted by 
telephone by a physician (BZ), and these patients all pre-
ferred to postpone the medical procedures because of  
80% ribavirin cumulative dosage and 80% of  the dura-
tion of  therapy[16]).
Ethics
The entire study design was evaluated by the Ethics Com-
mittee of  Spedali Civili of  Brescia and fully approved on 
July 31st, 2007. The study was registered with EudraCT, 
number 2008-001283-37.
Statistical analysis
Treatment efficacy was measured according to the inten-
tion to treat (ITT) criteria, including all patients who had 
received at least one dose of  interferon and one dose of  
ribavirin after signing the informed consent form. For 
statistical analyses, an unpaired t-test and Fisher’s exact 
test were used when appropriate using GraphPad Prism, 
version 5.0 (Graph Pad Software, Inc., San Diego, CA, 
United States). Logistic regression analysis was performed 
to assess the effect of  baseline features on efficacy and 
was completed using Stata software (version 7, StataCorp 
LP, College Station, TX, United States). A P value < 0.05 
was accepted to reject the null hypothesis.
RESULTS
Identification of the cohort
From November 2007 to December 2009, a cohort of  
162 HCVAb+ IDUs was identified by six SerT in the 
District of  Brescia. Most patients were Italian males with 
a low level of  education. At the time of  recruitment, one 
third of  the patients were unemployed, and one quarter 
Table 1  Main baseline characteristics of 162 hepatitis C 
antibody+ illicit drug users selected by physicians operating 
in six Territorial Addiction Service in the District of Brescia 
and comparison with 39 hepatitis C antibody+ illicit drug 
users accepting antiviral therapy  n  (%)
Patient characteristics Selected by SerT 
(n  = 162)
Accepting therapy 
(n  = 39)
P  
value
Male gender 135 (83) 27 (69) 0.8152
Age, yr, mean ± SD 38 ± 7 39 ± 6 0.8888
Spoken language: 
Italian
152 (94) 33 (85) 0.0912
Place of birth 0.1502
   Italy 147 (91) 32 (82)
   EU   5 (3) 2 (5)
   Non-EU 10 (6) 5 (13)
Level of education (n = 151) 0.8320
   ≤ 8 yr of school 118 (79) 30 (77)
   High school diploma   32 (21)   8 (21)
   University degree   1 (0) 1 (2)
(n = 149) 1.0000
Unemployed 49 (33) 13 (33)
Chronic associated 
conditions
41 (25) 11 (28) 0.6888
   Cardiovascular 5 (3) 2 (5)
   Respiratory 4 (2) 1 (3)
   Allergic 2 (1) 1 (3)
   Psychiatric 19 (12) 3 (8)
SerT: Territorial Addiction Service. 
Selected by SerT
(n  = 162)
Accepting therapy
(n  = 39)
P  value
Alcohol
   Active 11 (7)   4 (10) 0.4972
   Partial remission   5 (3) 0 (0) 0.5867
   Total remission   23 (14) 10 (26) 0.0944
Cannabis
   Active   7 (11) 2 (5) 0.0590
   Partial remission 3 (2) 1 (3) 0.5811
   Total remission 4 (2) 3 (8) 0.1344
Cocaine
   Active 33 (20) 3 (8) 0.0038
   Partial remission 6 (4) 1 (3) 1.0000
   Total remission 39 (24) 12 (31) 0.4150
Heroin
   Active 48 (30)   6 (15) 0.1059
   Partial remission 19 (12)   5 (13) 0.7885
   Total remission 74 (46) 23 (59) 0.0647
Duration of 
intravenous drug 
use, yr, mean ± SD 
(range) 
(n = 98) (n = 33)
13 ± 8 (7-34) 13 ± 9 (6-32) 0.8588
Opiate substitution 
treatment
  126 (78)   28 (72) 0.4089
Methadone, mg, 
mean ± SD
  107 (66), 41 ± 22   19 (60), 46 ± 26 0.0642
Buprenorphine, 
mg, mean ± SD 
19 (12), 5 ± 3 9 (23), 6 ± 4 0.0751
A smoking habit was concomitant in 100% of patients: < 5 cigarettes/d 
in 4%, 5-10 cigarettes/d in 12%, 11-20 cigarettes/d in 54% and > 20 ciga-
rettes/d in 30%. SerT: Territorial Addiction Service.
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other priorities.
CHC was confirmed in 54 IDUs (33% of  the total), 
of  which 13 patients had a confirmed HCV RNA-nega-
tive test, with an estimated rate of  spontaneous clearance 
of  19%. Five patients had medical contraindications to 
specific antiviral therapy (two cases of  decompensated 
cirrhosis, one case of  hepatocellular carcinoma, one 
case of  pregnancy and one case of  uncontrolled severe 
psychiatric illness). The remaining 49 patients were of-
fered specific treatment for CHC, and 39 accepted and 
signed the informed consent form (80% acceptance rate). 
Two patients never started treatment after signing the 
informed consent form and were thus excluded from the 
ITT analysis, and two patients, one with HCV genotype 
1a and the other with HCV genotype 3a, relapsed after 
the end of  therapy and asked for a second cycle of  antivi-
ral therapy (after a 6-mo wash-out period). We therefore 
report results for 39 treatments in 37 patients.
Baseline characteristics of treated patients
The virologic features of  the treated patients are reported 
in Figure 2. The most represented HCV genotype was 
type 1 (13 patients with 1a and seven with 1b). The HCV 
RNA baseline level, available in 36 of  39 patients, was 
over 5.6 Log/mL in 22 cases (61%). In total, 36% of  our 
patients were active illicit drug users, mainly using heroin; 
approximately one third had a history of  depression; one 
quarter had a pathologic Hamilton score for anxiety or 
depression; four patients were addicted to alcohol; and 
seven patients had an AUDIT-C at-risk score (Table 4). As 
reported in Table 5, several prognostic factors negatively 
affecting the outcome of  antiviral therapy for CHC were 
well represented among our treated IDUs. These factors 
included age over 40 years, male gender, overweight body 
type, previous unsuccessful HCV antiviral treatment, un-
favourable HCV virologic genotype or viral load, earlier 
contact with HBV, steatosis and progression to cirrhosis.
Safety
Two SAEs occurred during the study period, leading to 
therapy discontinuation: a case of  psychosis and a case 
of  pneumonia with suspected tuberculosis at weeks 4 
and 10, respectively. Three patients dropped out without 
Table 3  Attitudes toward/knowledge about hepatitis C virus 
infection among the hepatitis C antibody+ illicit drug users 
selected by the Territorial Addiction Service in comparison 
with hepatitis C antibody+ illicit drug users accepting 
antiviral therapy  n  (%)
Patient attitudes/knowledge Selected by SerT 
(n  = 162)
Accepting therapy 
(n  = 39)
P  
value
Source of HCV information (n = 150) (n = 33) NS
Other HCV patients 44 (29) 11 (33)
Health operators 72 (48) 18 (55)
Press 54 (36) 14 (42)
Web 15 (10)   6 (18)
Television 62 (41) 16 (48)
None 25 (17)   6 (18)
Feelings toward information
Complete (n = 139) 72 (52) (n = 32) 15 (47) 0.6964
Confident (n = 131) 30 (23) (n = 31) 16 (52) 0.0033
Reassuring (n = 130) 68 (52) (n = 28) 14 (50) 0.8381
Attitudes toward HCV therapy
Total fright   (n = 129) 3 (2) (n = 29) 0 (0) 1.0000
Moderate worries (n = 141) 102 (78) (n = 32) 25 (78) 0.5271
Positive expectations   (n = 125) 70 (56) (n = 28) 18 (64) 0.5271
HCV: Hepatitis C virus; SerT: Territorial Addiction Service. 
162 IDUs identified by SerT
106 agreed to first hepatologic visit
67 completed diagnostic procedure
54  had confirmed CHC
39 accepted therapy
56 never called for 
appointment
39 did not attend 
second visit
13 had spontaneous viral 
clearance
5  contraindications 
10 refusals 
Figure 1  Patient disposition according to the study protocol. CHC: Chron-
ic hepatitis C; IDU: Illicit drug user; SerT: Territorial Addiction Service. 
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medical need and were lost to follow-up; all dropouts oc-
curred within the first 8 wk of  antiviral treatment. Sixteen 
(41%) and 17 (44%) patients needed a dose adjustment 
of  pegylated interferon and ribavirin, respectively. In six 
patients (15%), the use of  erythropoietin was offered. 
The use of  leucocyte grown factors was not necessary for 
any patient. One patient became pregnant during the 6 
mo after the end of  therapy and decided on an abortion 
for personal reasons.
Efficacy
In the ITT analysis, 23 patients achieved an ETR (59%), 
and nine (23%) relapsed during the 6 mo after the end 
of  therapy. Fourteen patients achieved an SVR (36%), 
seven of  whom were infected with an unfavourable HCV 
genotype (Figure 3). The HCV RNA serologic clearance 
rates at weeks 4 and 12 are reported in Figure 4. Short-
term therapy was offered to nine patients, according to 
the study protocol, and did not negatively affect the SVR 
rate based on univariate analysis.
Adherence and prognostic factors for response
According to our adherence definition, 31 patients (80%) 
were compliant with the study protocol.
In the univariate logistic regression analysis, the ac-
tive use of  cocaine and/or heroin, ongoing substitution 
treatment, the type of  substitution treatment, the pres-
ence of  comorbidity, spoken language and male gender 
did not affect the rate of  the SVR, whereas alcohol intake 
was associated with a non-response (P = 0.0018, 95%CI: 
0.0058-0.4565), independent of  the dose and type of  al-
coholic beverage.
DISCUSSION
Our study indicates that antiviral treatment for CHC in 
IDUs is safe and effective and that a multidisciplinary 
approach is a key element of  the care of  such patients. 
We have considered three main aspects of  this issue to 
understand whether these patients are, as generally per-
ceived, difficult to reach, manage or treat.
Table 5  Main baseline features potentially affecting the 
response to antiviral therapy in treated illicit drug users
Features Prevalence
Age over 40 yr 54%
Males 85%
BMI over 25 kg/m2 36%
Previous unsuccessful interferon treatment 21%
Unfavourable HCV genotype (1 or 4) 60%
HCV viral load > 5.6 Log (IU/mL) 62%
HBcAb positivity 40%
Ultrasonography suggestive of steatosis 44%
Ultrasonography suggestive of cirrhosis 17%
HBcAb: Hepatitis B core antibody; HCV: Hepatitis C virus; BMI: Body 
mass index.
Table 4  Main baseline clinical and laboratory characteristics 
of treated illicit drug users
Characteristics n  = 39
BMI (kg/m2), M (range)         24.3 (17.6-34.6)
Duration of HCV infection (yr), M (range)      5 (1-21)
Duration under 1 yr 14 (36)
Duration of IDU status (yr), M (range)    12 (1-32)
Active IDU 14 (36)
History of depression 11 (28)
Pathologic Hamilton score
Anxiety 10 (26)
Depression   8 (21)
AUDIT-C at-risk score   7 (18)
Leucocytes (n/mm3), M (range)        6960 (3960-11960)
Haemoglobin (g/dL), M (range)     15.5 (11.8-17.7)
Platelets   224 (106-421)
ALT index (value/u.l.n.), M (range)    2.5 (0.5-16.4)
AST index (value/u.l.n.), M (range) 2.0 (06-6.6)
GGT index (value/u.l.n.), M (range)    1.2 (0.3-13.9)
HCV: Hepatitis C virus; IDU: Illicit drug user; M: Male; BMI: Body mass 
index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; 
GGT: Gamma glutamyltransferase. 
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Figure 3  Percentage of end of treatment responses and sustained viro-
logic responses in the entire cohort and according to Hepatitis C virus 
genotype (G). ETR: End of treatment response; SVR: Sustained virologic 
response. 
Figure 4  Percentage of rapid virologic responses and early virologic re-
sponses in the entire cohort and according to Hepatitis C virus genotype 
(G). RVR: Rapid virologic response; EVR: Early virologic response.
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Are IDUS difficult to reach? 
IDUs, together with migrants and prison inmates, are 
regarded as special population groups. As recommended 
by an official position paper on behalf  of  several Italian 
scientific societies[13], in such vulnerable people, specific 
intervention is mandatory to identify, prevent and treat 
chronic viral infections of  the liver. In our approach, 
collaboration with the territorial services involved in the 
care of  addicts was the key means of  reaching IDUs 
(of  whom 6%-15% were migrants) who were at risk of  
exclusion from medical care for social reasons. In total, 
65% of  IDUs with HCVAb positivity and identified by 
physicians of  the SerT agreed to and received a dedicated 
medical visit that, even in the case of  patients not receiv-
ing treatment, provided an instructive opportunity for 
counselling on HCV transmission, the prevention of  liver 
complications, healthy lifestyle and available therapeutic 
protocols. In contrast, 56 IDUs (35% of  the total cohort 
identified by the SerT) never called for an appointment, 
despite an initial statement of  interest in the project. 
Moreover, after the first medical evaluation, 39 patients 
(37% of  the patients who agreed to the first visit) never 
completed the diagnostic procedure, even after encour-
agement by direct telephone contact with a physician. 
Because of  incomplete procedures, clinical and labora-
tory data were not sufficient to confirm an active HCV 
infection and to stage liver disease in 95 patients (59% of  
the initial cohort). Such a finding indicates that difficulties 
in reaching and motivating this population of  patients 
persist even in the context of  a well-organised multidisci-
plinary approach.
Are IDUs difficult to manage? 
Concerns about treating IDUs are mainly due to suspi-
cion of  low adherence, the risk of  SAEs (typically psy-
chiatric) and the inability to follow therapeutic prescrip-
tions[10]. In our study, adherence was high and comparable 
to the adherence reported for clinical trials in the general 
population[17,18]. The use of  a psychiatric questionnaire to 
monitor depression and anxiety was well accepted; one 
patient received antidepressant therapy before starting 
antiviral treatment, and paroxetine was offered to another 
patient after 12 wk of  antiviral treatment. The patient 
with a psychotic reaction completely recovered after the 
withdrawal of  antiviral treatment without consequences 
or the need for psychiatric drugs. These data on the psy-
chiatric safety of  CHC treatment in IDUs, as previously 
suggested by other studies[19-22], are encouraging.
An important feature of  our study was the inclusion 
of  people who were actively addicted, with no period of  
mandatory abstinence; 36% of  our enrolled patients con-
tinued to use illicit drugs (mainly heroin and cocaine) dur-
ing the study protocol. Despite this “difficult to manage” 
characteristic, the data on safety, efficacy and adherence 
are encouraging. Moreover, logistic regression failed to 
demonstrate a negative correlation with the viral response 
to therapy in patients who were actively addicted during 
antiviral treatment. Only alcohol consumption was relat-
ed to a lower SVR rate, and this finding confirms the role 
of  alcohol consumption in the impairment of  antiviral 
treatment efficacy, which has already been demonstrated 
in the general population[23].
Although IDUs are considered to be poorly mo-
tivated to undergo medical care, the multidisciplinary 
setting and strict collaboration among the different physi-
cians involved in the care of  the IDUs led to a high rate 
of  access to therapy; 76% of  patients with confirmed 
CHC started treatment. Such a rate was markedly higher 
than the rate previously reported in studies in the general 
population[10].
Are IDUs difficult to treat?
Adherence to treatment was high (80%), and despite few 
withdrawals for safety reasons, the overall SVR of  36% 
was lower than expected for the general population. This 
“efficacy” goal must be observed in light of  several “dif-
ficult to treat” characteristics in our study population[24]. 
Among our IDUs, viral features such as HCV genotype 1 
and a high baseline level of  viremia were prevalent. More-
over, 40% of  our patients tested positive for HBcAb[25]. 
Male gender, an overweight body type and an age over 
40 were frequent. Other unfavourable factors affecting 
the virologic response were a relatively high prevalence 
of  steatosis and cirrhosis in 44% and 17%, respectively, 
of  patients. Most patients had been addicted for over 10 
years, and no patient was identified and treated during the 
acute phase of  the infection. In total, 21% of  patients 
experienced the failure of  at least one antiviral treatment 
for CHC. A few of  these features are not modifiable 
(HCV genotype, viral load and gender), whereas other 
features could be modified by a more prompt strategy of  
intervention (younger age, shorter duration of  infection 
and lower score of  fibrosis).
In conclusion, IDUs with HCV-related CHC, actively 
using illicit drugs and/or opioid substitution treatment, 
can be successfully treated in a multidisciplinary setting 
with a standard antiviral combination of  ribavirin and pe-
gylated interferon, with good adherence and a good safe-
ty profile. IDUs’ “difficult to reach, manage and treat” 
characteristics should not be used to contraindicate anti-
viral therapy. An appropriate multidisciplinary setting is 
a key factor in overcoming the “difficult” characteristics 
of  these patients, with a strategic aim of  reducing HCV 
circulation in the largest reservoir of  this viral infection. 
Whether treatment will benefit from upcoming new anti-
viral agents is currently under study in our unit.
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Background
Hepatitis C virus (HCV) infection is a common condition worldwide with preva-
lence of 3%. Illicit drug users (IDUs) are regarded as an important reservoir of 
this infection and as “super-spreaders”. HCV infection is a progression disease 
possibly leading to chronic liver disease and ultimately to end stage liver dis-
ease. Is therefore important to identify strategy to eradicate infection particularly 
in the reservoir-population? Concerns about therapy of HCV infection in these 
populations are present in both physicians and IDUs.
Innovations and breakthroughs
The investigators report that within a multidisciplinary setting involving both liver 
and addiction specialists nearly half of identified HCV+ IDUs accept hepatologic 
counseling and nearly a quarter accept treatment. Eighty percent of treated 
patients are adherent to treatment according to 80/80/80 rule. Sustained viro-
logical response is achieved in a proportion similar of that reported in registra-
tion trials, is not influenced by ongoing addiction, but is negatively affected by 
alcohol consumption. Incidence of psychiatric and organic side effects is not 
different from that reported in the general population.
Applications
This article supports the concept that barriers to HCV therapy of IDUs can be 
overcome in the context of a multidisciplinary team, and that in this clinical 
context adherence and efficacy of therapy is similar as in the general popula-
tion. The study highlights the point that the risk of HCV spreading by the super-
spreaders IDUs can be reduced and that their habits can not be used as an 
argument to withhold antiviral therapy.
Peer review
The study includes challenging for ethical difficulty of HCV treatment. It’s very 
interesting and authors may applaudable effort on this study. Of course, op-
posite opinions for HCV treatment on addicts may exist, nonetheless this study 
indicates possibility of HCV treatment for some addicts if patients can receive 
enough support from medical profession. Although this study may raise an ethi-
cal issue, it will give a strong impact to readers and make fascinating reading.
REFERENCES
1 World Health Organization. Global Alert and Response: 
Hepatitis C. http: //www.who.int/csr/disease/hepatitis/
whocdscsrlyo2003/en/index1.html. Accessed January 14, 
2013
2 Vezali E, Aghemo A, Colombo M. A review of the treat-
ment of chronic hepatitis C virus infection in cirrhosis. Clin 
Ther 2010; 32: 2117-2138 [PMID: 21316532 DOI: 10.1016/
j.clinthera.2010.12.013]
3 Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith 
BD, Lesesne SB. Forecasting the morbidity and mortality as-
sociated with prevalent cases of pre-cirrhotic chronic hepati-
tis C in the United States. Dig Liver Dis 2011; 43: 66-72 [PMID: 
20739252 DOI: 10.1016/j.dld.2010.05.006]
4 Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in 
active drug users. N Engl J Med 2001; 345: 215-217 [PMID: 
11463020]
5 Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Kat-
soulidou A, Belshaw R, Fraser C, Pybus OG, Hatzakis A. 
Integrating phylodynamics and epidemiology to estimate 
transmission diversity in viral epidemics. PLoS Comput Biol 
2013; 9: e1002876 [PMID: 23382662 DOI: 10.1371/journal.
pcbi.1002876]
6 National Institutes of Health Consensus Development Con-
ference Statement: Management of hepatitis C 2002 (June 
10-12, 2002). Gastroenterology 2002; 123: 2082-2099 [PMID: 
12454863]
7 Dienstag JL, McHutchison JG. American Gastroenterological 
Association technical review on the management of hepa-
titis C. Gastroenterology 2006; 130: 231-64; quiz 214-7 [PMID: 
16401486]
8 Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, 
management, and treatment of hepatitis C: an update. Hepa-
tology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/
hep.22759]
9 Edlin BR, Kresina TF, Raymond DB, Carden MR, Goure-
vitch MN, Rich JD, Cheever LW, Cargill VA. Overcoming 
barriers to prevention, care, and treatment of hepatitis C in 
illicit drug users. Clin Infect Dis 2005; 40 Suppl 5: S276-S285 
[PMID: 15768335]
10 Zanini B, Lanzini A. Antiviral treatment for chronic hepa-
titis C in illicit drug users: a systematic review. Antivir Ther 
2009; 14: 467-479 [PMID: 19578232]
11 Belfiori B, Chiodera A, Ciliegi P, Tosti A, Baldelli F, Stagni G, 
Francisci D. Treatment for hepatitis C virus in injection drug 
users on opioid replacement therapy: a prospective mul-
ticentre study. Eur J Gastroenterol Hepatol 2007; 19: 731-732 
[PMID: 17625449]
12 Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caro-
leo B, Armignacco O, Carioti J, Maio G, Monarca R, Antinori 
A. Effectiveness of a multi-disciplinary standardized man-
agement model in the treatment of chronic hepatitis C in 
drug addicts engaged in detoxification programmes. Addic-
tion 2007; 102: 423-431 [PMID: 17298650]
13 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte 
D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta 
F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, 
Scotto G, Starnini G. Recommendations for the prevention, 
diagnosis, and treatment of chronic hepatitis B and C in 
special population groups (migrants, intravenous drug users 
and prison inmates). Dig Liver Dis 2011; 43: 589-595 [PMID: 
21256097 DOI: 10.1016/j.dld.2010.12.004]
14 Zanini B, Covolo L, Donato F, Lanzini A. Effectiveness and 
tolerability of combination treatment of chronic hepatitis C 
in illicit drug users: meta-analysis of prospective studies. 
Clin Ther 2010; 32: 2139-2159 [PMID: 21316533 DOI: 10.1016/
S0149-2918(11)00021-X]
15 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach 
V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. 
CTCAE v3.0: development of a comprehensive grading sys-
tem for the adverse effects of cancer treatment. Semin Radiat 
Oncol 2003; 13: 176-181 [PMID: 12903007]
16 McHutchison JG, Manns M, Patel K, Poynard T, Lindsay 
KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albre-
cht JK. Adherence to combination therapy enhances sus-
tained response in genotype-1-infected patients with chronic 
hepatitis C. Gastroenterology 2002; 123: 1061-1069 [PMID: 
12360468]
17 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff-
man M, Reindollar R, Goodman ZD, Koury K, Ling M, 
Albrecht JK. Peginterferon alfa-2b plus ribavirin compared 
with interferon alfa-2b plus ribavirin for initial treatment 
of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 
958-965 [PMID: 11583749]
18 Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, 
Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux 
D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a 
plus ribavirin for chronic hepatitis C virus infection. N Engl J 
Med 2002; 347: 975-982 [PMID: 12324553]
19 Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, 
Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig 
A, Loeschke K. Adherence and mental side effects during 
hepatitis C treatment with interferon alfa and ribavirin in 
psychiatric risk groups. Hepatology 2003; 37: 443-451 [PMID: 
12540795]
20 Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich 
M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, 
Ziemer M, Gutsche J, Weich V, Halangk J, Berg T. Hepatitis 
C treatment in “difficult-to-treat” psychiatric patients with 
pegylated interferon-alpha and ribavirin: response and 
psychiatric side effects. Hepatology 2007; 46: 991-998 [PMID: 
17668880]
21 Sylvestre DL, Clements BJ. Adherence to hepatitis C treat-
ment in recovering heroin users maintained on methadone. 
Zanini B et al . Management of addicts with HCV
 COMMENTS
8019 November 28, 2013|Volume 19|Issue 44|WJG|www.wjgnet.com
Eur J Gastroenterol Hepatol 2007; 19: 741-747 [PMID: 17700258]
22 Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara 
M, Weltman M. Clinical experience with the treatment of 
hepatitis C infection in patients on opioid pharmacotherapy. 
Addiction 2011; 106: 977-984 [PMID: 21205057 DOI: 10.1111/
j.1360-0443.2010.03347.x]
23 Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. 
Semin Liver Dis 2009; 29: 188-199 [PMID: 19387918 DOI: 
10.1055/s-0029-1214374]
24 Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago 
M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon-
Domanec I, DeMasi R, Picchio G, Witek J, Zeuzem S. Predic-
tors of virologic response with telaprevir-based combination 
treatment in HCV genotype 1-infected patients with prior 
peginterferon/ribavirin treatment failure: post-hoc analysis 
of the phase III realize study. Hepatology 2011; 54: 375A-376A
25 Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini 
P, Piccinino F. HCV genotype and “silent” HBV coinfection: 
two main risk factors for a more severe liver disease. J Med 
Virol 2001; 64: 350-355 [PMID: 11424125]
P- Reviewers: Yoshida S, Zhao HT    S- Editor: Song XX 
L- Editor: A    E- Editor: Zhang DN
Zanini B et al . Management of addicts with HCV
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Published by Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza, 
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4   4
